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Association between depressive symptoms,
use of antidepressant medication and the
metabolic syndrome: the Maine-Syracuse
Study
Georgina E. Crichton1*, Merrill F. Elias2,3 and Michael A. Robbins2,3
Abstract
Background: Both depression and the metabolic syndrome (MetS) are two major public health issues. The aim of
this study was to examine associations between depressive symptoms, the use of antidepressant medications, and
the prevalence of MetS.
Methods: Cross-sectional analyses were undertaken on 970 participants from the Maine-Syracuse Study. Depressive
symptoms were measured using two self-reported depression scales, the Center for Epidemiological Studies Depression
Scale (CES-D), and the Zung self-rating depression scale. Antidepressant medication use was also self-reported. MetS
was defined according to the recent harmonized criteria.
Results: The risk of MetS were approximately 79 and 86 % higher for those in the highest quartile for the CESD and
the Zung (CES-D: OR = 1.79, p = 0.003; Zung: OR = 1.71, p = 0.006), compared to those in the lowest quartile. With
adjustment for socio-demographic variables, lifestyle factors and C-reactive protein (CRP), risk was attenuated, but
remained statistically significant for the CES-D. In those who reported using antidepressant medication, the odds of
having MetS were over 2-fold higher (OR = 2.22, p < 0.001, fully adjusted model), compared to those who did not use
antidepressants. Both measures of depressed mood were also associated with low high density-lipoprotein (HDL)
cholesterol levels. Antidepressant use was associated with elevated fasting plasma glucose concentrations,
hypertension, and low HDL-cholesterol.
Conclusion: Depressive symptoms and the use of antidepressant medications are associated with the prevalence of
MetS, and with some of the individual components of the syndrome.
Keywords: Depressed mood, Antidepressants, Metabolic syndrome
Background
The clustering together of abdominal obesity, hyperten-
sion, dyslipidemia and insulin resistance is referred to as
the metabolic syndrome (MetS). A syndrome can be
regarded as “a clustering of factors that occur together
more often than by chance alone and for which the
cause is often uncertain” ([1], p.1641). The worldwide
prevalence of MetS is increasing, in part attributable to
the rise in obesity [1]. While there is not a single known
cause for MetS, a number of non-modifiable factors in-
cluding age, genetics, ethnicity and sex, influence the syn-
drome’s prevalence [2]. Having MetS is associated with a
1.7-fold increase in the risk for cardiovascular disease
(CVD) [3]. For non-diabetics with MetS, the likelihood of
developing future type 2 diabetes increases seven-fold [4],
further augmenting CVD risk. The presence of MetS may
also be a future predictor of mortality [5, 6]. Research is
needed to generate public health measures to combat
MetS and develop interventions for at-risk individuals.
Like MetS, depression is associated with an increased
risk of diabetes [7] and CVD [8]. Depression is one of
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the most common psychological illnesses affecting adults
in the United States (US), with over 15 million adults
having had at least one major depressive episode in 2013
[9]. With both MetS and depression being recognised as
major public health challenges, attention has been drawn
to associations between the two.
A recent systematic review and meta-analysis investi-
gated the current evidence for an association between
depression and MetS from 29 cross-sectional and 11 pro-
spective studies [10], and concluded that a bidirectional
association exists. While a growing amount of literature
suggests that depressive symptoms and more severe de-
pressive episodes are associated with MetS [10–13], some
inconsistent results have been reported [14, 15], and the
direction of this association remains uncertain.
Fewer studies have examined any association between
antidepressant use and MetS. A recent study suggests that
antidepressants are a stronger predictor of type 2 diabetes
than are depressive symptoms [16]. As antidepressants
may directly effect components of MetS, in particular,
weight gain [17–19], it is important to consider antidepres-
sant use in relation to the syndrome. The PPP-Botnia Study
(PPP = prevalence, prediction, and prevention of diabetes),
a large Finnish population-based study, recently examined
associations between depressive symptoms, use of anti-
depressant medication and MetS [20]. In this study the
odds for having MetS increased over 10 % for each stand-
ard deviation increase in depressive symptoms, and users of
antidepressant medication had more than 50 % increased
odds for having MetS. More studies such as this one are
needed to extend what is currently known about these rela-
tions. Few, if any, studies have used more than a single de-
pression scale, and it is important to know if similar results
are obtained for two different mesures of depressed mood.
Therefore, the present study also reports associations
between depressive symptoms using two different self-
report scales one prominent in the epidemiology literature
(Zung) and one prominent in the psychology literature
(CES-D), antidepressant use, and MetS prevalence, and
also tests relations with the individual components of
MetS, in a US community-based sample. Further, we
examine if any potential associations vary according to
apolipoprotein ε4 (APOE ε4) status. It is hypothesized that
there will be a positive association between self-reported
depressive symptoms and MetS prevalence, and that those
on antidepressant medication will have a higher likelihood
of having MetS.
Methods
Participants
Data were obtained from participants of the Maine-
Syracuse Longitudinal Study (MSLS), which commenced
in 1975 and was designed to measure blood pressure
and cognitive performance [21, 22] and expanded at
Wave 6 to examine other cardiovascular risk factors.
The MSLS employs a time-lagged-longitudinal-cohort
design with new subjects featuring an initial wave of
data collection and then new subjects recruited into
the study every five years with the same recruitment
procedures as employed for every wave.
Sample characteristics at Wave 6 (Table 1) differed in
two ways from those at the initial wave of testing, ap-
proximately 25 years earlier. Subjects were older (Wave
1 mean age = 48.0 ± 16.0 years), there were fewer women
(Wave 1 proportion = 56 %), and mean blood pressures
were lower due to the need to treat subjects once hyper-
tension was detected (Wave 1: mean systolic = 137 ±
28 mmHg, mean diastolic = 82 ± 18 mmHg). In this con-
text, it is important to note that our analysis was cross-
sectional at Wave 6 and our goal was not to duplicate
sample charcteristics from a study begun years ealier.
No comparison between our MetS data or our covariates
at Wave 6 with Wave 1 are possible because data pertienet
to MetS were all collected for the first time at Wave 6.
The only recruitment exclusions (common to all waves)
were institutionalization, diagnosed psychiatric disorder
and alcoholism. Participants for the present study were
those returning for the sixth (2001-2006) study wave. De-
tails of initial study recruitment have been previously
described [21–24]. Beginning with 1049 individuals, par-
ticipants for the present study were excluded for the fol-
lowing reasons: missing cardiometabolic, depression or
medication data (n = 36), acute stroke (n = 28), probable
dementia (n = 8), undertaking dialysis treatment (n = 5),
inability to read English (n = 1), and prior alcohol abuse
(n = 1). The final sample with complete wave 6 data com-
prised 970 individuals, aged 23 to 98 years.
Stroke, defined as a focal neurological deficit of acute
onset persisting more than 24 h, was based on self-report
and was confirmed by a record review indicating a diagno-
sis of acute stroke. Clinical diagnoses of dementia were
determined from cognitive data and medical records using
the National Institute of Neurological and Communicative
Diseases and Stroke/Alzheimer’s Disease and Related Dis-
orders Association (NINCDS-ADRDA) criteria [25] and
confirmed using the ICD-10 Guidelines [26].
Ethics, consent and permissions
This study was conducted according to the guidelines
established by the Declaration of Helsinki and all proce-
dures were approved by the University of Maine Institu-
tional Review Board. Written informed consent was
obtained from all subjects.
Procedure
Metabolic syndrome
Metabolic syndrome was defined according to the Inter-
national Diabetes Federation and the American Heart
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Association/National Heart, Lung, and Blood Institute,
which requires 3 of 5 risk factors to be present [1]
namely abdominal obesity (WHO waist circumference
cut-offs for Caucasian population: men ≥94 cm, women
≥80 cm), elevated blood pressure (systolic: ≥130 and/or
diastolic ≥85 mmHg), elevated fasting plasma glucose
(≥5.6 mmol/L or ≥100 mg/dL), elevated triglycerides
(≥1.7 mmol/L or ≥150 mg/dL), reduced high density
lipoprotein (HDL) cholesterol (<1.0 mmol/L or <40 mg/
dL for males; <1.3 mmol/L or <50 mg/dL for females).
Standard assay methods were employed [21] to obtain
fasting plasma glucose (mg/dL), total cholesterol (TC,
mg/dL), low-density lipoprotein cholesterol (LDL, mg/
dL), high-density lipoprotein cholesterol (HDL, mg/dL),
triglycerides (mg/dL) and C-reactive protein (CRP, mg/
L), following an overnight fast. Waist circumference (in
centimetres) was taken over light clothing, using a non-
extendable measuring tape, at the level of the iliac crest.
Automated blood pressure measures (GE DINAMAP
100DPC-120XEN, GE Healthcare) were taken five times
each in reclining, sitting and standing after a supine rest
for 15 min, and averaged over the 15 assessments to ob-
tain mean systolic blood pressure (BP) and diastolic BP.
Depressed mood
Depressive symptoms were assessed using the Center for
Epidemiological Studies Depression Scale (CES-D) [27]
and the Zung self-rating depression scale [28]. The CES-
D consists of 20 statements about feelings (e.g., happy,
fearful, depressed) and behaviors (e.g., crying, eating,
sleeping) and participants are required to indicate how
often they have felt or behaved in these ways within the
past week on a 4-point scale (from none of the time (0),
to all of the time (3)). Total scores range from 0 to 60,
with higher scores indicating a greater number of symp-
toms. A total score of 16 or higher is considered to indi-
cate depressed mood.
The Zung self-rating depression scale [28] consists of
20 statements about feelings and symptoms of depres-
sion, such as sleep and appetite. Each statement is rated
by the participant on a 4-point scale, ranging from 1) a
little of the time, to 4) most of the time. Total scores
were multipled by 1.25 to given a final scale ranging
from 25 to 100, with higher scores indicating more de-
pressive symptoms. A score of 62.5 or higher is consid-
ered to indicate depressed mood. Both scales have
demonstrated reliability and validity [29–32]. The use of
antidepressant medication was self-reported in the Nu-
trition and Health Questionnaire [33, 34].
Other health and demographic variables
Demographic, socioeconomic and lifestyle characteristics
were obtained from the Nutrition and Health Question-
naire [33, 34]. Education level (years) was obtained
through self-report and ranged from 4 to 20 years. Phys-
ical activity was measured with the Nurses’ Health Study
Activity Questionnaire, a validated measure of time spent
Table 1 Demographic, cardiovascular and health variables for
Maine-Syracuse Longitudinal Study (N= 970) participants according
to metabolic syndrome status
MetS
Variable No Yes P-value
n = 539 n = 431
M or % SD M or % SD
Age, years 60.7 13.4 63.7 11.9 <0.001
Gender 0.1
Males 38.8 43.9
Females 61.2 56.1
Education, years 15.1 2.6 14.1 2.7 <0.001
Race 0.019
Caucasian 94.2 90.3
African American 5.8 9.7
Smoking, no cigarettes/day 1.0 4.2 1.8 6.4 0.027
BMI, kg/m2 27.1 4.5 32.1 6.2 <0.001
Physical activity,
MET mins/daya
1517 1803 880 1370 <0.001
Total cholesterol, mg/dL 204.8 37.1 197.0 42.2 0.002
HDL cholesterol, mg/dL 59.2 5.2 46.7 12.4 <0.001
LDL cholesterol, mg/dL 125.8 32.0 114.5 33.8 <0.001
Systolic BP, mmHg 124.8 21.0 138.5 19.9 <0.001
Diastolic BP, mmHg 68.6 9.9 72.8 9.7 <0.001
Fasting blood glucose, mg/dL 90.6 15.4 109.5 35.9 <0.001
Waist circumference, cm 88.8 12.4 103.6 14.0 <0.001
CRP, mg/L 0.36 0.43 0.52 0.53 <0.001
Triglycerides, mg/dL 101.9 47.0 192.4 143.3 <0.001
Alcohol intake, g/week 41.6 74.6 29.2 62.3 0.006
Depressed mood, CES-D scoreb 6.8 6.4 8.5 7.3 <0.001
Depressed mood, Zung scoreb 41.1 8.5 43.8 10.1 <0.001
% using antidepressants 8.3 15.1 0.001
% Obese (BMI≥ 30 kg/m2) 20.8 61.4 <0.001
% Diabetes mellitusc 2.0 25.5 <0.001
% Hypertensiond 40.8 87.5 <0.001
% CVDe 8.0 22.0 <0.001
% APOE ε4 26.9 27.0 0.9
APOE ε4 apolipoprotein ε4, BMI body mass index, BP blood pressure, CES-D
Center for Epidemiologic Studies Depression Scale, CRP C-reactive protein, CVD
cardiovascular disease, MetS metabolic syndrome, MET metabolic equivalent,
MSLS Maine-Syracuse Longitudinal Study
aIncludes moderate and intense self-reported physical activity
bHigher scores indicates greater number of depressive symptoms
cFasting plasma glucose ≥ 126 mg/dL or taking anti-diabetic medication
dSystolic BP≥ 140 mmHg and/or diastolic BP≥ 90 mmHg or taking
anti-hypertensive medication
eIncludes myocardial infarction, coronary artery disease, heart failure, angina
pectoris, transient ischemic attack
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engaging in various physical activities [35]. MET-hours
per week for each activity were calculated and summed to
give total MET-minutes per week [36]. Smoking status
was based on self-report from the Nutrition and Health
Questionnaire [37].
Diabetes mellitus was defined as having a fasting
plasma glucose ≥ 126 mg/dl or taking anti-diabetic medi-
cation, and CVD was considered present if any of the
following were present: myocardial infarction, coronary
artery disease, heart failure, angina pectoris, or transient
ischemic attack.
Statistical analyses
Participant demographics, health and psychological vari-
ables were compared according to MetS status (yes/no).
Independent samples t-tests were used for continuous
variables and Chi-square for categorical variables for the
analyses involving demographic variables.
Logistic regression analyses were used to determine
whether depressive symptoms (CES-D and Zung) and
antidepressant use (yes/no) were associated with MetS.
After determining that the relation between depressive
symptoms and MetS was not linear, the analysis was per-
formed using scores from each quartile. The three high-
est quartiles were compared with the lowest quartile
(reference group). Odds ratios (OR) and 95 % confidence
intervals (CI) were computed. Potential confounding
variables were selected if they correlated with both de-
pressive symptoms and MetS, or were of theoretical or
clinical importance. The following covariance models
were employed to adjust for confounding in the primary
analysis:
Model 1: Basic: age (years) + gender + education (years) +
ethnicity;
Model 2: Basic + smoking (cigarettes/day), physical
activity (MET hours/week), CRP (mg/L).
In addition, the odds of having any of the individual
MetS components were determined according to depres-
sive symptoms (CES-D and Zung) and antidepressant use
in the MSLS. The same two covariate sets were used.
Sensitivity analyses
Analyses examining relations between depressive symp-
toms and MetS were performed again, excluding partici-
pants reporting use of antidepressants. Further, the same
analyses examining potential associations between depres-
sive symptoms and MetS, and between antidepressant use
and MetS, were performed after excluding individuals
with existing type 2 diabetes or CVD.
To test if any of the potential associations differed for
men and women, or according to age, interaction terms
(sex*depressive symptoms, sex*antidepressant medication
use; age*depressive symptoms, age*antidepressant medica-
tion use) were calculated and added to the basic models.
As other studies have shown that the influence of de-
pressive symptoms may be greater for individuals with
the apolipoprotein E4 (APOE ε4) allele compared to
those without the allele, for example, on cognitive func-
tioning [38], we also tested the possibility that the APOE
ε4 allele modifies the relation between depressed mood
and MetS, i.e. interaction terms (APOE ε4*depressive
symptoms, APOE ε4*antidepressant medication use) were
calculated and added to the basic models.
Due to the established effect of depressive symptoms
on neuropathologial changes in brain regions, the ana-
lyses were repeated with a comprehensive measure of
global cognitive function (the MSLS global cognitive
composite score) added to the extended model. Finally,
as antidepressant medication may impact upon body
weight, in a final step, weight was added to the extended
model examining the association between antidepressant
use and MetS.
Results
Demographic and preliminary findings
The demographic, cardiovascular and health variables
for MSLS (N = 970) participants according to MetS sta-
tus are shown in Table 1. Those with MetS were slightly
older, smoked more, had a higher mean BMI and re-
ported less physical activity. They had significantly lower
HDL-, LDL- and total cholesterol than those without
MetS; and, as would be expected, they had significantly
higher systolic BP, diastolic BP, fasting blood glucose,
waist circumference, and triglycerides. Those with MetS
reported significantly more depressive symptoms, as
measured by both scales, than those without MetS. In
total, 110 participants (33 males and 77 females; 11.3 %
of the sample), reported using antidepressant medica-
tion. Of those taking antidepressants, a significantly
higher proportion had MetS than did not. Depressive
symptoms were associated with use of antidepressant
medication. Those with scores in the highest quartile of
depressed mood had significantly higher odds of using
antidepressants compared to those with scores in the
lowest quartile (basic models: Zung: OR: 4.67, 95 % CI:
2.40–9.08, P < 0.001; CES-D: OR: 3.46, 95 % CI: 1.86–
6.46, P < 0.001) (data not shown). The CES-D and Zung
were highly correlated with each other (Pearsons r = 0.61,
P < 0.001).
Main findings
Depressive symptoms and MetS
Those with the highest quartile of scores on the CES-D
had a 79 % higher risk of having MetS (basic model, OR:
1.79, P < 0.01), and those with the highest quartile of
scores on the Zung had a 71 % higher risk of having
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MetS (basic model, OR: 1.71, P < 0.01), compared to
those with scores in the lowest quartile (Table 2). Those
with scores in the second and third quartiles did not dif-
fer significantly (P > 0.05) from those with the lowest
scores in terms of MetS risk, for either of the depressed
mood measures.
For the extended model (addition of risk factor covari-
ates), relations between depressed mood and MetS seen
with the basic mode (age, education, gener and ethni-
city) remained significant for the CES-D, with some at-
tenuation of risk (see Table 2). Those with scores in the
highest qurtile on the CES-D had a significantly higher
risk for MetS, compared to those with scores in the low-
est quartile.
Antidepressant medication use and MetS
Those on antidepressants (n = 110, 11.3 % of the sample)
had slightly over a two-fold increase in relative risk for
MetS, compared to those not taking antidepressants (ex-
tended model: OR = 2.22, P < 0.001) (Table 2).
Depressive symptoms, antidepressant medication and
individual MetS components
Those with the highest scores on both the CES-D and the
Zung (highest quartiles) had a significantly increased like-
lihood of having low HDL-cholesterol (CES-D: OR: 1.89,
P < 0.01; Zung: OR: 1.48, P < 0.05; basic model) (Table 3).
The association between higher CES-D scores and risk for
low HDL-cholesterol remained significant with addition of
covariates, but was no longer significant for the Zung.
Neither depressed mood measure was associated with any
of the other individual MetS components.
Antidepressant use was significantly associated with
higher odds for having elevated glucose levels, hyperten-
sion, and low HDL-cholesterol with full covariate adjust-
ment (extended models, all P < 0.05) (Table 4).
Secondary analyses
In a secondary set of analyses, neither of the age, sex or
APOE ε4 interaction terms added to the basic model
were significant (all P values >0.4, data not shown). Ex-
cluding participants with either CVD or diabetes did not
change the pattern of results. Controlling for cognition
(global composite score) in the extended model did not
Table 2 Odds of having metabolic syndrome according to
presence of depressive symptoms and use of antidepressant
medications in the Maine-Syracuse Longitudinal Study
Depressive symptoms/
medication use
Covariate
seta
Quartile
of scoresb
MetS
OR 95 % CI P-value
CES-D score Basic Q4 1.79 1.22, 2.62 0.003
Q3 1.35 0.93, 1.97 0.1
Q2 1.05 0.72, 1.54 0.8
Q1 1.00
Extended Q4 1.50 1.00, 2.24 0.049
Q3 1.23 0.83, 1.82 0.3
Q2 0.99 0.66, 1.49 0.9
Q1 1.00
Zung score Basic Q4 1.71 1.17, 2.50 0.006
Q3 1.20 0.81, 1.77 0.4
Q2 1.14 0.79, 1.65 0.5
Q1 1.00
Extended Q4 1.43 0.99, 2.50 0.1
Q3 0.99 0.66, 1.52 0.9
Q2 1.05 0.71, 1.54 0.8
Q1 1.00
Antidepressant
medication use
Basic Yes 2.31 1.51, 3.54 <0.001
No 1.00
Extended Yes 2.22 1.42, 3.48 <0.001
No 1.00
CES-D Center for Epidemiologic Studies Depression Scale, CI confidence
interval, MetS metabolic syndrome, OR odds ratio
aBasic: adjusted for age, education, sex, ethnicity; Extended: adjusted for set 1 +
smoking (cigarettes per day), physical activity (MET-minutes/day), CRP (mg/L)
bQuartile 1 (lowest quartile of scores) = reference group
Table 3 Odds of having individual metabolic syndrome
components according to depressed mood in the Maine-Syracuse
Longitudinal Study
Depressive
symptoms
Covariate
seta
Quartile
of scoresb
MetS low HDL-cholesterolc
OR 95 % CI P
CES-D score Basic Q4 1.89 1.30, 2.74 0.001
Q3 1.28 0.89, 1.85 0.2
Q2 1.41 0.98, 2.04 0.1
Q1 1.00
Extended Q4 1.67 1.13, 2.46 0.010
Q3 1.21 0.83, 1.77 0.3
Q2 1.34 0.91, 1.98 0.1
Q1 1.00
Zung score Basic Q4 1.48 1.02, 2.14 0.037
Q3 1.36 0.93, 1.99 0.1
Q2 1.01 0.71, 1.44 0.9
Q1 1.00
Extended Q4 1.30 0.88, 1.91 0.2
Q3 1.26 0.84, 1.87 0.3
Q2 0.99 0.69, 1.44 0.9
Q1 1.00
CES-D Center for Epidemiologic Studies Depression Scale; CI confidence
interval; MetS metabolic syndrome; OR odds ratio
aBasic: adjusted for age, education, sex, ethnicity; Extended: adjusted for set 1 +
smoking (cigarettes per day), physical activity (MET-minutes/day), CRP (mg/L)
bQuartile 1 (lowest quartile of scores) = reference group
cMetS clinical cut off points: reduced HDL-cholesterol: <1.0 mmol/L or <40 mg/dL
for males; <1.3 mmol/L or <50 mg/dL for females [1]
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change the results. Finally, there was no attenuation of
the results when body weight was added to the extended
model testing the association between antidepressant
use and MetS.
Availability of data and materials
The dataset supporting the conclusions of this article
are available from the authors upon request.
Discussion
We have observed a significant association between ele-
vated depressive symptoms and greater prevalence of
MetS, controlling for socio-demographics, lifestyle fac-
tors and CRP. The findings were consistent across two
different scales measuring the same construct (basic
model). Few, if any, studies have examined relations be-
tween depressed mood using two different scales and
this is necessary to the development of consistent oper-
ational definitions of depressed mood. Good cognitive
studies, as an example, employ more than one index of a
cognitive domain to define that domain. Our second
major finding was that antidepressant use was associated
with over 2-fold increased risk for MetS, adjusted for
socio-demographics, lifestyle factors and CRP. Of the in-
dividual MetS components, low HDL-cholesterol was
related to both measures of depressed mood, and anti-
depressant use was significantly related to elevated glu-
cose levels, hypertension, and low HDL-cholesterol.
The results of the analyses indicate that the risk for
MetS is not distributed equally across all quartiles of the
depressed mood scale distribution. It was the individuals
with depressed mood scores in the highest quartile that
exhibited a significantly increased risk for MetS, com-
pared to those individuals with scores in the lowest
quartile. This makes sense from a clinical perspective as
one would expect that the more extreme levels of de-
pressed mood would be related to MetS. In the extended
model, these statistically significant associations between
the highest quartile of scores and MetS were attenuated
but remained significant for the CES-D. This suggests
that the presence of cardiovascular risk factors, such as
inflammation, smoking or physical activity, attenuate the
relations between depressed mood and MetS, and that
this phenomenon is related to the fact that depressed
mood raises the risk for CVD [8] and conversely the
presence of CVD can lead to depression [39].
As a distinguishing factor from other studies, we were
able to also assess if the results varied according to
APOE ε4 status. No difference was found between those
with and without at least one allele. The study included
participants across a wide age range. Age may impact
upon one’s cognitive abilities in relation to self-reported
depressive symptoms. We found no evidence for an
interaction between age and the depressive symptom
measures. In addition, statistically controlling for cogni-
tive function (adding the global composite score to the
extended model) did not change the results.
Our findings are consistent with numerous other stud-
ies which have shown positive associations between
depression and MetS. Pan et al [10] reviewed both
cross-sectional studies, and prospective studies that re-
ported odds ratios for depression as the outcome, and
OR for MetS as the outcome. Depression and MetS were
correlated in cross-sectional studies, and a bidirectional
association was observed in the prospective studies.
Multivariate logistic regression with depression as the
dependent variable yielded an OR of 1.27 (95 % CI 1.07–
1.51) (based on 11 studies). Of note, this review included
studies using both a self-reported symptom scale and
diagnostic interview to assess depression. Interestingly,
the association was slightly weaker when depression was
assessed by diagnostic interview rather than self-reported
(OR = 1.29 vs. 1.51) [10]. Data on antidepressant medica-
tion use was not examined in this review.
Our study examined depressive symptoms, assessed
through the completion of self-rated scales, reliant upon
the participant’s perception of symptom burden. Other
studies have demonstrated a similar pattern of association
with clinically diagnosed depressive disorders established
objectively using standardized diagnostic interviews. A
number of studies have shown positive relations between
major depressive disorder (both current and lifetime) and
Table 4 Odds of having individual metabolic syndrome components according to use of antidepressant medications in the Maine-
Syracuse Longitudinal Study
Predictor Covariate seta Group MetS elevated glucoseb MetS hypertensionb MetS low HDL-cholesterolb
OR 95 % CI P OR 95 % CI P OR 95 % CI P
Antidepressant medication use Basic Yes 2.01 1.30, 3.13 0.002 1.99 1.21, 3.25 0.006 1.66 1.10, 2.51 0.015
No 1.00 1.00 1.00
Extended Yes 1.95 1.23, 3.09 0.005 1.81 1.09, 3.02 0.023 1.57 1.03, 2.40 0.036
No 1.00 1.00 1.00
CI, confidence interval; MetS, metabolic syndrome; OR, odds ratio
aBasic: adjusted for age, education, sex, ethnicity; Extended: adjusted for set 1 + smoking (cigarettes per day), physical activity (MET-minutes/day), CRP (mg/L)
bMetS clinical cut off points: elevated fasting plasma glucose: ≥5.6 mmol/L or ≥100 mg/dL; elevated blood pressure: systolic: ≥130 and/or diastolic ≥85 mmHg;
reduced HDL-cholesterol: <1.0 mmol/L or <40 mg/dL for males; <1.3 mmol/L or <50 mg/dL for females [1]
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MetS [11–13]. For example, Butnoriene et al [11] showed
a significant relation between major depressive disorder
(both current and lifetime) and depressive symptoms
with MetS prevalence in a community sample. Data
from the National Health and Nutrition Examination
Survey (NHANES III) obtained from young adults found
that a history of major depression was associated with in-
creased odds of MetS in women, but not in men [13].
Similarly, Goldbacher et al [40] showed that a lifetime his-
tory of major depression predicted an increased risk of de-
veloping MetS in middle-aged women.
We found that depressive symptoms may be directly
associated with HDL-cholesterol levels. Other studies
investigating depression in relation to the individual
components of MetS have shown significant and inde-
pendent associations between low HDL-cholesterol
[20, 41], as well as large waist circumference [20, 41],
hypertension [13], and high triglycerides [13, 20] with de-
pression. In the present study, antidepressant use was as-
sociated with higher glucose and blood pressure levels,
and lower HDL-cholesterol. Use of antidepressant medica-
tion has been previously associated with higher triglycer-
ides, systolic BP, and waist circumference [20]. Weight
gain during antidepressant treatment can be either a sign
of improvement in patients who have weight loss as a
symptom of depression, or may be a residual symptom of
weight gain from overeating when depressed [18]. Sub-
stantial weight gain during the early phase of treatment
with antidepressants or weight gain that continues despite
the resolution of depressive symptoms may be a side-
effect of the drug treatment [18]. A review by Newcomer
and Haupt [42] indeed concluded that antipsychotic medi-
cations may be associated with adverse metabolic effects,
including weight gain and decreases in insulin sensitivity,
which may further contribute to increasing plasma glu-
cose and lipid levels, and therefore MetS risk.
Mechanisms
There are a number of potential mechanisms that may
underlie the association between depressed mood and
MetS. Firstly, depression has been associated with obesity
[43], inflammation [44], and insulin resistance [45], which
are all linked with MetS. Inflammation as a consequence
of obesity is likely to be a central component [41, 46]. De-
pression may facilitate physiological changes, such as dys-
regulation of the hypothalamus-pituitary-adrenal (HPA)
axis, resulting in increased secretion of corticotrophin-
releasing hormone, adrenocorticotropic hormone, and cor-
tisol [47]. This promotes deposition of visceral fat tissue,
which secretes inflammatory cytokines implicated in insu-
lin resistance, a key factor in MetS. Cortisol also inhibits
lipid mobilization, directly effecting dyslipidemia [14, 41].
Alternatively, depressed mood may result in increased
consumption of food and/or alcohol as a means for coping
with negative emotion, promoting weight gain and subse-
quently activating an inflammatory response [12]. Other
negative, depression-related behaviours, such as the con-
sumption of an unhealthy diet, engaging in little physical
activity and poor sleep patterns may enhance oxidative
stress, adiposity, inflammation, and an increased risk for
metabolic disturbances [12, 48, 49].
Implications
Individuals with elevated depressive symptoms, even
without major depressive disorder, and individuals taking
antidepressant medication should be considered at risk
for MetS. Assessment and monitoring of MetS compo-
nents should be routine care for these people [50]. Life-
style changes could be recommended if patients are
found to be at increased risk for cardiometabolic risk
factors. The use of self-reported depression symptom
scales are therefore clinically important for identifying
individuals at risk for more severe depression and meta-
bolic sequela. Contrary to a few studies and consistent
with others we find no relation higher risk for MetS in
persons carrying one or two APOE ε4 alleles.
Limitations
Due to the cross-sectional design, we are only able to
infer an association between elevated depressive symp-
toms, antidepressant use, and higher MetS prevalence.
No inferences regarding causality can be made. The re-
sults may not be generalizable to the African American
community as they only comprised a small proportion
of the sample (7.5 %). Finally, not all possible relevant
lifestyle behaviors or social psychological variables were
included in the study. Other inflammatory markers, such
as leptin and adiponectin were not measured. We also
did not have data on family history of depression or dis-
ease, which may have an effect on our findings, but was
not a question raised in this study. Absence of data on
duration of treatment with antidepressant medications is
a limitation, albeit our major outcomes for inferring de-
pression (more specifically depressed mood) were the two
depressed mood scales.
Strengths
The major strengths of the study include the representa-
tive, community-based sample of men and women, the
assessment of MetS criteria, depressive symptoms, car-
diovascular risk varibles and other health and lifestyle
factors, and the fact that examiners were blind to the
subject’s MetS status.
Conclusions
Depressive symptoms are associated with an increased
prevalence of MetS. Those taking antidepressants have
over twice the likelihood of having MetS, compared with
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those not taking such medication. Well-designed longi-
tudinal studies are required to examine the chrono-
logical sequence of the development of depression and
MetS. More studies are also needed to examine the
biological and behavioral mechanisms underlying this
depression-MetS relation, important for the prevention
and management of both.
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